Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Paraganglioma × 3-Iodobenzylguanidine × Clear all

Phase

Phase 2 2 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1 CNS 1

Conditions

Neuroblastoma 7 Recurrence 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Neoplasms 1 Ganglioneuroblastoma 1

Interventions

Everolimus 2 vandetanib 1 spartalizumab 1 gallium Ga 68 dotatate 1 fludarabine phosphate 1 cixutumumab 1 Specimen Handling 1 Salts 1 Octreotide 1 Magnetic Resonance Spectroscopy 1 Interleukin-13 1 Fluorodeoxyglucose F18 1 Cyclophosphamide 1 Biopsy 1 Acetates 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡